mercaptopurine and Ataxia-Telangiectasia

mercaptopurine has been researched along with Ataxia-Telangiectasia* in 2 studies

Other Studies

2 other study(ies) available for mercaptopurine and Ataxia-Telangiectasia

ArticleYear
Biomarkers and Precision Therapy for Primary Immunodeficiencies: An In Vitro Study Based on Induced Pluripotent Stem Cells From Patients.
    Clinical pharmacology and therapeutics, 2020, Volume: 108, Issue:2

    Ataxia telangiectasia (AT) and Aicardi-Goutières syndrome (AGS) are inherited disorders of immunity with prevalent neurological phenotype. Available treatments are only partially effective, and the prognosis is poor. Induced pluripotent stem cells (iPSCs) are obtained by reprogramming patient somatic cells, preserving the donor individual genetic heritage and creating patient-specific disease models, useful to investigate pathogenesis and drug effects and to develop precision therapies. The aim is to investigate the cytotoxicity of a panel of immunomodulators using iPSCs of patients with AT or different forms of AGS (AGS1, AGS2, and AGS7). iPSCs were obtained by reprogramming AT and AGS patients' cells and, as a control, the BJ normal human fibroblast line, using Sendai virus. Cytotoxic effects of two drugs proposed to treat respectively AT and AGS (dexamethasone and mepacrine) were tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay after 72 hours' exposure. Data were obtained also for other immunomodulatory drugs (thioguanine, mercaptopurine, thalidomide, and lenalidomide). Relative expression of genes involved in the tested drug pathways was analyzed. AGS7-derived iPSCs displayed altered viability when treated with a low dose of mepacrine and higher expression of cyclic guanosine monophosphate-adenosine monophosphate synthase, which is the main target for mepacrine action. AGS7-derived iPSCs were also more sensitive to thioguanine, while AGS2 and AT iPSCs were less sensitive to this medication than the BJ-iPSC. All iPSCs were equally sensitive to mercaptopurine and resistant to dexamethasone, thalidomide, and lenalidomide. This work establishes an innovative in vitro model that is useful to investigate the mechanisms of drugs potentially effective in AT and AGS.

    Topics: Ataxia Telangiectasia; Autoimmune Diseases of the Nervous System; Biomarkers; Cell Line; Cell Proliferation; Cell Survival; Clinical Decision-Making; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance; Genetic Predisposition to Disease; Humans; Immunologic Factors; Induced Pluripotent Stem Cells; Lenalidomide; Mercaptopurine; Nervous System Malformations; Phenotype; Precision Medicine; Predictive Value of Tests; Quinacrine; Thalidomide; Thioguanine

2020
Responses of Fanconi anemia fibroblasts to adenine and purine analogues.
    Mutation research, 1981, Volume: 80, Issue:2

    Fanconi anemia (FA) fibroblasts are known to be exceptionally sensitive to the cytotoxic action of mitomycin C (MMC). The survival of FA cells was enhanced significantly when 0.5 mM caffeine or 0.5 mM adenine was added for 72 h after the cells were exposed to MMC. In other experiments in which MMC was not used, FA fibroblasts were shown to be significantly more sensitive than control cells to 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and 6-azauridine (6-AU). These observations offer a new approach to defining the basic biochemical defect in FA.

    Topics: Anemia, Aplastic; Ataxia Telangiectasia; Azauridine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Fanconi Anemia; Humans; Mercaptopurine; Mitomycins; Skin; Thioguanine

1981